II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Ekaterini Simões Goudouris, Almerinda Maria do Rego Silva, Aluce Loureiro Ouricuri, Anete Sevciovic Grumach, Antonio Condino-Neto, Beatriz Tavares Costa-Carvalho, Carolina Cardoso Prando, Cristina Maria Kokron, Dewton de Moraes Vasconcelos, Fabíola Scancetti Tavares, Gesmar Rodrigues Silva Segundo, Irma Cecília Barreto, Mayra de Barros Dorna, Myrthes Anna Barros, Wilma Carvalho Neves Forte, Ekaterini Simões Goudouris, Almerinda Maria do Rego Silva, Aluce Loureiro Ouricuri, Anete Sevciovic Grumach, Antonio Condino-Neto, Beatriz Tavares Costa-Carvalho, Carolina Cardoso Prando, Cristina Maria Kokron, Dewton de Moraes Vasconcelos, Fabíola Scancetti Tavares, Gesmar Rodrigues Silva Segundo, Irma Cecília Barreto, Mayra de Barros Dorna, Myrthes Anna Barros, Wilma Carvalho Neves Forte

Abstract

In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.

Conflict of interest statement

Conflict of interest: none.

Figures

Figure 1. Post-infusion serum concentration of immunoglobulin…
Figure 1. Post-infusion serum concentration of immunoglobulin G in patients on regular use of human immunoglobulin. Comparison of intravenous and subcutaneous immunoglobulin

References

    1. Costa-Carvalho BT, Solé D, Condino A, Neto, Rosário N., Filho I Consenso Brasileiro sobre o Uso de Imunoglobulina Humana em Pacientes com Imunodeficiências Primárias. Rev Bras Alerg Imunopatol. 2010;33(3):104–116.
    1. Ochs HD, Hagin D. Primary immunodeficiency disorders: general classification, new molecular insights, and practical approach to diagnosis and treatment. Ann Allergy Asthma Immunol. 2014;112(6):489–495. Review.
    1. Rezaei N, Vries ED, Gambineri E, Haddad E. Common presentations and diagnostic approaches. In: Sullivan KE, Stiehm ER, editors, editors. Stiehm’s Immune Deficiencies. United States: Elsevier; 2014. pp. 3–58.
    1. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, et al. The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2015;35(8):727–738. Review.
    1. Abolhassani H, Asgardoon MH, Rezaei N, Hammarstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229–1243. Review.
    1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the nternational Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726. Review.
    1. Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M, Condino A, Neto, Costa-Carvalho BT, Grumach AS, Quezada A, Patiño P, Franco JL, Porras O, Rodríguez FJ, Espinosa-Rosales FJ, Espinosa-Padilla SE, Almillategui D, Martínez C, Tafur JR, Valentín M, Benarroch L, Barroso R, Sorensen RU, Latin American Group for Primary Immunodeficiency Diseases Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol. 2007;27(1):101–108.
    1. Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158(Suppl 1):14–22. Review.
    1. Errante PR, Franco JL, Espinosa-Rosales FJ, Sorensen R, Condino A., Neto Advances in primary immunodeficiency diseases in Latin America: epidemiology, research, and perspectives. Ann N Y Acad Sci. 2012;1250:62–72. Review.
    1. Grimbacher B. ESID Registry Working Party The European Society for Immunodeficiencies (ESID) registry 2014. Clin Exp Immunol. 2014;178(Suppl 1):18–20.
    1. Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954–961.
    1. Mahlaoui N, Gathmann B, Kindle G, Ehl S, Quinti I, Grimbacher B. The European Society for Immunodeficiencies (ESID) Registry: recent advances in the epidemiology of Primary Immunodeficiencies and how does that translate in clinical care. Rare Dis Orphan Drugs. 2014;1(4 Suppl 4):25–27. on behalf of the ESID Registry Working Party Steering Committee (Isabella Quinti, Italy, Bodo Grimbacher, Germany, Matthew Buckland, United Kingdom, Markus Seidel, Austria, Joris van Montfrans, The Netherlands) and the ESID Society.
    1. Modell V, Quinn J, Orange J, Notarangelo LD, Modell F. Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network. Immunol Res. 2016;64(3):736–753.
    1. Oncley J, Melin M, Richert D, Cameron J, Gross P. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1 lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71(2):541–550.
    1. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737–764. viii. Review.
    1. Berger M, Stiehm ER. From subcutaneous to intravenous immunoglobulin and back. In: Etzioni A, Ochs HD, editors, editors. Primary immunodeficiency disorders: a historic and scientific perspective. United States: Academic Press; 2014. pp. 307–377.
    1. Bruton O. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728.
    1. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153–1164.
    1. Wasserman RL, Stein M, Melamed I, Kobrynski LJ, Gupta S, Puck J, et al. Long-term efficacy and safety of recombinant human hyaluronidase (rHuPH20)- facilitated subcutaneous infusion of immunoglobulin G (IgG) (HyQvia; IGHy) in patients with primary immunodeficiencies (PI) AB96J Allergy Clin Immunol. 2015;135(2 Suppl)
    1. Skoda-Smith S, Torgerson T, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.
    1. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med. 1980;93(1):55–56.
    1. Roord JJ, van der Meer JW, Kuis W, de Windt GE, Zegers BJ, van Furth R, et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet. 1982;1(8273):689–690.
    1. Ugazio AG, Duse M, Re R, Mangili G, Burgio GR. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. 226Lancet. 1982;1(8265)
    1. Roord JJ, van der Meer JW, Kuis W, van Furth R. Treatment of antibody deficiency syndromes with subcutaneous infusion of gamma globulin. Birth Defects Orig Artic Ser. 1983;19(3):217–221. Review.
    1. Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol. 1988;73(1):160–162.
    1. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162–166.
    1. Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: the European experience. Curr Opin Allergy Clin Immunol. 2013;13(6):623–629. Review.
    1. Gardulf A, Andersen V, Björkander J, Ericson D, Frøland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345(8946):365–369.
    1. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.
    1. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1–7. Review.
    1. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol. 2006;26(2):177–185.
    1. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21(2):105–116. Review.
    1. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51–59. Review.
    1. Berger M, Murphy E, Riley P, Bergman GE, VIRTUE Trial Investigators Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–863.
    1. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277–287.
    1. Shapiro R. Subcutaneous immunoglobulin. Immunol Allergy Clin North Am. 2012 In press.
    1. Bezrodnik L, Gómez Raccio A, Belardinelli G, Regairaz L, Diaz Ballve D, Seminario G, et al. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol. 2013;33(7):1216–1222.
    1. Bonagura VR. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Ann Allergy Asthma Immunol. 2013;111(6 Suppl):S10–S13. Review.
    1. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, Patel S, Boutboul D, Marson MN, Gérard L, Lee M, Watier H, Oksenhendler E.DEFI study group Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186–194.
    1. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73(12):1307–1319. Review.
    1. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities--ongoing questions. J Clin Immunol. 2013;33(Suppl 2):S99–103.
    1. Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2016;12(5):595–602. Review.
    1. Sewell WA, Kerr J, Behr-Gross ME, Peter HH.Kreuth Ig Working Group European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014;44(8):2207–2214.
    1. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP, Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU, American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–63. Erratum in: Ann Allergy Asthma Immunol. 2006;96(3):504.
    1. Bonagura VR. Dose and outcomes in primary immunodeficiency disorders. Clin Exp Immunol. 2014;178(Suppl 1):7–9.
    1. Chapel H, Prevot J, Gaspar HB, Español T, Bonilla FA, Solis L, Drabwell J, Editorial Board for Working Party on Principles of Care at IPOPI Primary immune deficiencies - principles of care. 627Front Immunol. 2014;5 Review.
    1. Condino A, Neto, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr) 2014;42(3):245–260. Review.
    1. Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6(7):853–869. Review.
    1. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075–1077.
    1. Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT.Inter-University Working Party for the Study of Immune Deficiencies The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3):165–174.
    1. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803–819. ix. Review.
    1. Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255–263.
    1. Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med. 2006;73(2):133–7, 140, 143-4. Review.
    1. Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am. 2008;28(4):875–876.:x.
    1. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–1360.:e4.
    1. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.
    1. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;(24 Suppl 1):S28–S50. Review.
    1. Ballow M. Intravenous IgG replacement in PIDD: dose and clinical expectations. Immunol Allergy Clin North Am. 2012 In press.
    1. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172–181.
    1. Ballow MC. Immunoglobulin therapy: replacement and immunomodulation. In: Rich RR, editor, editor. Clinical immunology: principles and practice. 4th. United States: Elsevier; 2013. pp. 1041–1063.
    1. Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hipogammaglobulinemia. Pediatr Infect Dis J. 1988;7(5 Suppl):S92–S96.
    1. Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–1036.
    1. Notarangelo LD, Plebani A, Mazzolari E, Soresina A, Bondioni MP. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration. 2007;74(3):264–275. Review.
    1. Rich AL, Le Jeune IR, McDermott L, Kinnear WJ. Serial lung function tests in primary immune deficiency. Clin Exp Immunol. 2008;151(1):110–113.
    1. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–212.
    1. Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;(33) Suppl 2:S90–S94. Review.
    1. Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146–160. Review.
    1. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–942.
    1. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779–802.:viii. Review.
    1. American Academy of Allergy Asthma & Immunology Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency. 2011. [cited 2017 Feb 14]. Internet. .
    1. Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, Martín-Nalda A, Oliveras M, Martinez-Cutillas J, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014;34(8):1015–1017.
    1. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413–437.:x. Review.
    1. European Primary Immunodeficiencies Consensus Conference . Consensus Report and Recommendations. Germany: 2006. [cited 2017 Feb 14]. Jun 19-20, 2006. Internet. .
    1. Clark P, Wimperis J, Lunn M, Jones A, Herriot R, Wood D, et al. Clinical Guidelines for Immunoglobulin Use. 2nd. UK: Department of Health; 2012. [cited 2017 Feb 14]. 2012. Internet. .
    1. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C, Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–S553. Review. Erratum in: J Allergy Clin Immunol. 2006; 117(6):1483. Dosage error in article text.
    1. Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr. 2010;57(1):185–218. Review.
    1. Orange JS, Ochs HD, Cunningham-Rundles C. Prioritization of evidence-based indications for intravenous immunoglobulin. J Clin Immunol. 2013;33(6):1033–1036.
    1. Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunode ciency disorders. Immunotherapy. 2014;6(10):1113–1126. Review.
    1. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, Kobrynski LJ, Komarow HD, Mazer B, Nelson RP, Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU, Verbsky JW, Bernstein DI, Blessing-Moore J, Lang D, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller D, Spector SL, Tilles S, Wallace D. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–1205.:e1-78. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Review.
    1. Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Sewell WA, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe. 629Front Immunol. 2014;5 Review.
    1. Matucci A, Maggi E, Vultaggio A. Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. 690Front Immunol. 2015;5 Review.
    1. Grimbacher B, Schäffer AA, Peter HH. The genetics of hypogammaglobulinemia. Curr Allergy Asthma Rep. 2004;4(5):349–358. Review.
    1. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. 2008;28(4):833–849.:ix. Review.
    1. Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2015;15(6):505–513. Review.
    1. Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. 626Front Immunol. 2014;5 Review.
    1. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–111.
    1. Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–1106.
    1. Aguiar R, Araújo C, Martins-Coelho G, Isenberg D. Use of Rituximab in systemic lupus erythematosus: a single center experience over 14 Years. Arthritis Care Res (Hoboken) 2017;69(2):257–262.
    1. Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol. 2016;85(6):340–345.
    1. Spadaro G, Pecoraro A, De Renzo A, Della Pepa R, Genovese A. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol. 2016;166-167:103–104.
    1. Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol. 2009;82(2):143–147.
    1. Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2(5):594–600. Review.
    1. Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ, Nelson J, et al. Use of intravenous gama-globulin in antibody immunodeficiency: results of a multicenter trial. Clin Immunol Immunopathol. 1982;22(1):60–67.
    1. Roifman CM, Lederman HM, Lavi S, Stein LD, Levison H, Gelfand EW. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79(2):171–174.
    1. Buckley RH, Schiff RI. The use of intravenous immunoglobulin in immunodeficiency diseases. N Engl J Med. 1991;(325(2):110–117. Review.
    1. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001–1004.
    1. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37(5):396–404. Review.
    1. Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92(2):200–204.
    1. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–273.
    1. Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH.Vivaglobin Study Group Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15(6):238–245.
    1. Gregory R, Malcolmson C, Patel C, Woolley T, Jones A. Experience with a 20% subcutaneous immunoglobulin (Hizentra®) in children with primary immunodeficiency diseases - a single-center review. AB154J Allergy Clin Immunol. 2013;131(2)
    1. Bourdin A, Berger J, Früh A, Spertini F, Bugnon O. Subcutaneous immunoglobulin and support program: what level of interest of patients? Rev Med Suisse. 2015;11(469):831–835. French.
    1. Jolles S. Subcutaneous and intramuscular immune globulin therapy. 2016. [cited 2017 Feb 14]. Internet. UpToDate. .
    1. Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015;35(3):179–185.
    1. Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet. 1993;342(8884):1432–1433.
    1. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79(1):48–51.
    1. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96(10):1474–1478.
    1. Church JA, Howard V, Sleasman JW, Borte M, Berger M. Subcutaneous Immunoglobulin Replacement Therapy in Infants and Children with Primary Immunodeficiencies. AB213J Allergy Clin Immunol. 2011;127(2)
    1. Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatric Allergy Immunol. 2013;24(1):49–53.
    1. Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med. 2011;123(5):186–193.
    1. Gardulf A, Andersson E, Lindqvist M, Hansen S, Gustafson R. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol. 2001;21(2):150–154.
    1. Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013;173(2):365–371.
    1. Hodkinson JP, Lucas M, Lee M, Harrison M, Lunn MP, Chapel H. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin Exp Immunol. 2015;181(1):179–187.
    1. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008;28(4):765–778.:viii. Review.
    1. Späth PJ, Granata G, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. 11ReviewFront Immunol. 2015;6
    1. Sriaroon P, Ballow M. Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin North Am. 2015;35(4):713–730. Review.
    1. Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol. 2014;164(2):151–166. Review.
    1. International Patient Organisation for Primary Immunodeficiencies (IPOPI) The global organisation working to improve the quality of life for people with primary immunodeficiencies. Access to Immunoglobulin Therapies for patients living with a Primary Immunodeficiency. 2012. [cited 2017 Feb 14]. Internet. .
    1. Orange JS. Immune globulin therapy in primary immunodeficiency. 2015. [cited 2016 Feb 10]. Internet. UpToDate. .
    1. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26(6):813–827. Review.
    1. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16(7):696–707. Review.
    1. Andresen I, Kovarik JM, Psycher M, Bolli R. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G Formulations. J Clin Pharmacol. 2000;40(7):722–730.
    1. Hernandez-Trujillo HS, Chapel H, Lo Re V, 3rd, Notarangelo LD, Gathmann B, Grimbacher B, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169(1):57–69.
    1. Wasserman RL, Melamed I, Nelson RP, Jr, Knutsen AP, Fasano MB, Stein MR, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405–414.
    1. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol. 1994;14(2):90–97.
    1. Borte M, Quinti I, Soresina A, Fernández-Cruz E, Ritchie B, Schmidt DS, et al. Efficacy and safety of subcutaneous vivaglobin(R) replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011;31(6):952–961.
    1. Rojavin M, Sidhu J, Pfister M, Hubsch A. Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency. Clin Exp Immunol. 2014;178(Suppl 1):146–148.
    1. Koterba AP, Farnan K, Sierra C, Eufrasio D, Stein M. Experience with subcutaneous loading of vivaglobin or hizentra in primary immunodeficiency patients naive to immunoglobulin replacement therapy. A101Ann Allergy Asthma Immunol. 2012;109
    1. Koterba AP, Stein MR. Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy. 63Allergy Asthma Clin Immunol. 2014;11(1)
    1. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532–538. Review.
    1. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133–141.
    1. Younger ME, Blouin W, Duff C, Epland KB, Murphy E, Sedlak D. Subcutaneous immunoglobulin replacement therapy: ensuring success. J Infus Nurs. 2015;38(1):70–79. Review.
    1. Gustafson R, Gardulf A, Hansen S, Leibl H, Engl W, Lindén M, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008;152(2):274–279.
    1. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30(2):301–307.
    1. Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111(1):51–55.
    1. Younger ME, Aro L, Blouin W, Duff C, Epland KB, Murphy E, Sedlak D, Nurse Advisory Committee Immune Deficiency Foundation Nursing guidelines for administration of immunoglobulin replacement therapy. J Infus Nurs. 2013;36(1):58–68.
    1. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Adv Ther. 2011;28(7):521–533. Review.
    1. International Patient Organisation for Primary Immunodeficiencies (IPOPI) Primary immunodeficiencies. Patient Needs & Outlooks Survey: a Report based on 300 patient questionnaires. 2012. [cited 2016 June 6]. Internet. .
    1. Stein MR. Enzyme-facilitated subcutaneous IgG: changing the paradigm of IgG therapy. Immunol Allergy Clin North Am. 2012 In press.
    1. Ponsford M, Carne E, Kingdon C, Joyce C, Price C, Williams C, et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations. Clin Exp Immunol. 2015;182(3):302–313.
    1. Smith CI, Hammarström L. Intravenous immunoglobulin in pregnancy. Obstet Gynecol. 1985;66(3 Suppl):39S–40S.
    1. Williams PE, Leen CL, Heppleston AD, Yap PL. IgG replacement therapy for primary hypogammaglobulinaemia during pregnancy: report of 9 pregnancies in 4 patients. Blut. 1990;60(3):198–201.
    1. Memmedova L, Azarsiz E, Edeer Karaca N, Aksu G, Kutukculer N. Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Rep. 2013;5(3):e14.
    1. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178. Review.
    1. Brennan VM, Salomé-Bentley NJ, Chapel HM, Immunology Nurses Study Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133(2):247–251.
    1. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238–1239. Review.
    1. Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71–81. Review.
    1. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–259. Review.
    1. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38(1-3):122–132. Review.
    1. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139–145.
    1. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract. 2013;1(6):558–566.
    1. Bichuetti-Silva DC, Furlan FP, Nobre FA, Pereira CT, Goncalves TR, Gouveia-Pereira M, et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol. 2014;23(2):442–446.
    1. Ramírez E, Romero-Garrido JA, López-Granados E, Borobia AM, Pérez T, Medrano N, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res. 2014;133(6):1045–1051.
    1. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012;129(3):628–634. Review.
    1. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015–2025. Review.
    1. Bonilla FA. Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis. Clin Exp Immunol. 2014;178(Suppl 1):72–74.
    1. Silvergleid AJ, Ballow M, Schrier SL, Stiehm ER, Tirnauer JS, editors, editors. Overview of intravenous immune globulin (IVIG) therapy. 2016. [cited 2017 Feb 14]. Internet. UpToDate. .
    1. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006;91(8):651–654.
    1. Melamed I, Testori A, Spirer Z. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease. Int Rev Immunol. 2012;31(6):451–461. Review.
    1. Karakoç Aydıner E, Kıykım A, Barış S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars. 2016;51(1):8–14.
    1. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180–1192. Review.
    1. Bhole MV, Burton J, Chapel HM. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin North Am. 2008;28(4):821–832.:ix. Review.
    1. Markvardsen LH, Christiansen. I, Andersen H, Jakodsen J. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin. Basic Clin Pharmacol Toxicol. 2015;117(6):409–412.
    1. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65–72.
    1. Shah SN, Todoric K, Tarrant TK. Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease. Clin Case Rep Rev. 2015;1(7):151–152.
    1. Högy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6(1):24–29. Erratum in: Eur J Health Econ. 2005;6(3):243. Eur J Health Econ. 2008;9(2):203.
    1. Haddad L, Perrinet M, Parent D, Leroy-Cotteau A, Toguyeni E, Condette-Wojtasik G, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. Rev Med Interne. 2006;27(12):924–926. French.
    1. Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, Tajahmady A, Thomas C, Suarez F, Pellier I, Hermine O, Aladjidi N, Mahlaoui N, Fischer A, French PID study group CEREDIH Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240–245.
    1. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131(2):585–587.:e1-3.
    1. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60.
    1. Gerth WC, Betschel SD, Zbrozek AS. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. 23Allergy Asthma Clin Immunol. 2014;10(1)
    1. Carmo EV, Correa M, Mazzucchelli JL, Tavares L, Damasceno E, Costa-Carvalho BT. Socioeconomic impact of immunoglobulin replacement therapy for primary immunodeficiency patients on the health public system in Brazil: a single center study. A878Value Health. 2015;18(7)
    1. Shapiro R. Why I use subcutaneous immunoglobulin (SCIG) J Clin Immunol. 2013;33(Suppl 2):S95–S98. Review.
    1. Ochs HD, Lee ML, Fischer SH, Delson ES, Chang BS, Wedgwood RJ. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. J Infect Dis. 1987;156(4):652–654.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner